Subscribe
Subscribe
MY AMERICAN SCIENTIST
LOG IN! REGISTER!
SEARCH
 
Logo IMG
HOME > MULTIMEDIA > Multimedia Detail

SCIENCE IN THE NEWS DAILY

Study Suggests Drug Can Cut Risk of Cancer's Return

from the Baltimore Sun

CHICAGO (Associated Press) - A drug to prevent bone loss during breast cancer treatment also substantially cut the risk that the cancer would return, results that left doctors excited about a possible new way to fight the disease.

It is the first large study to affirm wider anti-cancer hopes for Zometa and other bone-building drugs called bisphosphonates. Zometa, made by Novartis AG, is used now for cancers that have already spread to the bone.

The new study involved 1,800 premenopausal women taking hormone treatments for early-stage breast cancer. Zometa cut by one-third the chances that cancer would recur—in their bones or anywhere else.

Read more ...


comments powered by Disqus
 

Connect With Us:

Facebook Icon Sm Twitter Icon Google+ Icon Pinterest Icon RSS Feed Instagram Icon

Latest Multimedia

PODCASTS: From Balloons to Space Stations: Studying Cosmic Rays

CREAM Inflating

Cosmic rays have mysterious qualities about them that scientists continue to research in order to better understand their origins and composition. Dr. Eun-Suk Seo, a professor of physics at the University of Maryland, and her colleagues, fly enormous balloons as large as a football stadium and a volume of 40-million-cubic feet for extended periods over Antarctica to study particles coming from cosmic rays before they break up in the atmosphere.

To view all multimedia content, click "Latest Multimedia."



RSS Feed Subscription

Receive notification when new content is posted from the entire website, or choose from the customized feeds available.


EMAIL TO A FRIEND :

Of Possible Interest

Science In The News Daily: Diesel Exhausts Do Cause Cancer, Says WHO

Science in the News Weekly: T-DM1 Treats Breast Cancer With Fewer Side Effects

Science In The News Daily: CT Scans on Children 'Could Triple Brain Cancer Risk'

Subscribe to American Scientist